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Open access under the ElsCurcumin is a polyphenolic nonﬂavonoid compound extracted from the rhizome of turmeric (Curcuma
longa), a plant commonly used in Indian and Chinese traditional medicine to treat rheumatism, cough,
inﬂammation and wounds. Curcumin putative targets, known based on studies of diverse central nervous
system disorders other than bipolar disorders (BD) include several proteins currently implicated in the
pathophysiology of BD. These targets include, but are not limited to, transcription factors activated by
environmental stressors and pro-inﬂammatory cytokines, protein kinases (PKA, PKC), enzymes, growth
factors, inﬂammatory mediators, and anti-apoptotic proteins (Bcl-XL). Herein, we review previous studies
on the anti-inﬂammatory and anti-oxidant properties of curcumin and discuss its therapeutic potential in
BD.
 2013 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
Bipolar disorder (BD) is a chronic, severe and prevalent mental
disorder associated with high rates of non-recovery, recurrence,
and chronicity [1,2]. Morbidity, mortality, and cost of illness stud-
ies indicate that BD is related to signiﬁcant burden [3,4]. Moreover,
for many affected individuals, BD is a progressive and accelerating
condition associated with neurostructural changes and cognitive
deterioration [5–7]. In addition to brain abnormalities, BD has been
linked to several metabolic alterations, including obesity, arterial
hypertension, and changes in glucose metabolism [8,9]. In fact,
metabolic syndrome and cardiovascular morbidity are one of the
most relevant causes of mortality in this population [10].
Evidence-based treatments for BD include the use of lithium,
several anticonvulsants, and atypical antipsychotics [11]. Studies
evaluating efﬁcacy and effectiveness indicate that most individuals
with BD fail to achieve symptomatic remission and functional
recovery with existing treatments alone or in combination [12].
Moreover, high rates of treatment discontinuation and switching
in BD are consequences of the limited efﬁcacy of available agents
[13]. Furthermore, tolerability concerns (e.g., weight gain) are ma-
jor limitations of current treatments [13].
It is generally accepted that existing treatments for BD are
capable of suppressing symptoms but have not been proven tooledo, 669 – 3rd Floor, Vila
man).
evier OA license.modify the underlying disease course and progression of the
illness. In addition to phenotypic/behavioral progression (e.g.,
shorter symptom-free intervals as a function of episode fre-
quency), pathological progression in BD has been reported at
the brain circuits, synaptic, cellular, intracellular, and neurochem-
ical levels [14]. In fact, BD is characterized by progressive
neuronal atrophy, cognitive deterioration functioning along with
shorter symptom-free intervals and lower treatment response
rates [15]. Mechanisms underlying neuroprogression are related
to imbalances between neurotoxicity and neuroprotection (i.e.,
neuroplasticity) [14].
The search for new, more efﬁcient, and safer drugs to treat BD
are an unmet need in psychiatry. For instance, the use of comple-
mentary and alternative medicines (CAM) offers a potentially
interesting resource [16]. Although the development of pragmatic
clinical trials for CAM in mood disorders began approximately
20 years ago, their off-label administration dates back to hundreds
or thousands of years [17]. Traditional cultures explored which
plants were useful for what conditions and passed information
on species, preparation, and dose through the ages [17]. There ap-
pears to be a high level of patient acceptance of this treatment
modality, notwithstanding the relative paucity of evidence sup-
porting their usage, as well as concerns regarding bioavailability
and manufacturer quality assurance [18]. Some CAM treatments
exhibit neurobiological effects that suggest possible application
in BD [19]. For example, over 3000 preclinical reports have de-
scribed pleotropic properties attributable to the herbal component
curcumin [20].
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from the rhizome of turmeric (Curcuma longa), a member of the
ginger family, and is commonly used as a culinary season in differ-
ent regions of India, China and other Asiatic countries [21]. In addi-
tion to its culinary use, turmeric has been used in these countries
as an anti-inﬂammatory agent [22], being used in traditional In-
dian medicine for rheumatism, cough, inﬂammation and wound
[23]. Turmeric has been studied in detail and all active ingredients
were isolated, including curcumin, which was described as the
most effective bioactive component [24]. As curcumin has low tox-
icity, it has been explored in medicine, based on its anti-oxidants
and anti-inﬂammatory properties. Accordingly, curcumin has been
studied in several diseases where inﬂammation and oxidative
stress imbalances are related to the pathophysiological mecha-
nisms, such as, Alzheimer’s and Parkinson’s disease [25], as well
as cardiovascular diseases and cancer [20,26,27].
Curcumin is often regarded as pleiotropic compound whose the
putative mechanisms of action are directed to several targets [28],
such cell proteins, including transcription factors (ATF-3, AP-1,
STAT-3, NF-jB), protein kinases (PKA, PKC), enzymes, growth fac-
tors, inﬂammatory mediators, and anti-apoptotic proteins (i.e.,
Bcl-XL) [21]. Because several of these targets have been implicated
in the pathophysiology of BD [29–31] or in the mechanisms of ac-
tion of current mood stabilizers [32,33], we postulated that curcu-
min could have therapeutic potential for the treatment of BD. In
this work, we review current evidences of the anti-inﬂammatory
and anti-oxidant properties of curcumin and propose that these ef-
fects may offer advantage for BD therapeutics.Neurotrophins, oxidative species and inﬂammation in bipolar
disorder: possible targets for curcumin
Although the pathophysiology of BD remains elusive, in the last
decade, ﬁndings from different modalities of research have con-
verged to demonstrate alterations in neuroplasticity, neuronal
interconnectivity, apoptosis regulation, cell survival and resilience
as critical processes in the patho-etiology and neuroprogression of
BD [34]. The balance between neuronal survival and death is regu-
lated or inﬂuenced by several mediators. Alterations in levels of
these substances in the periphery have been postulated as possible
biomarkers of BD [35]. The reproduction of abnormalities in neuro-
trophins, inﬂammatory mediators and oxidative species in inde-
pendent studies lead to the postulation that this combination can
be considered a viable biosignature and marker of progression in
BD [35]. Throughout this section, we discuss these mediators and
report the effects of curcumin on these potential therapeutic
targets.Neurotrophins
Neurotrophins are a family of proteins involved in neuronal
development, survival and neuronal functioning. The neurotrophin
called brain-derived neurotrophic factor (BDNF) is considered a
key mediator of neuroplasticity, being implicated in processes such
as neuronal differentiation, survival and synaptic plasticity [36].
Decreased serum BDNF levels in acute mood episodes of either
polarity in BD were recently conﬁrmed in a comprehensive a
meta-analysis [37]. Furthermore, clinical recovery is associated
with a corresponding increase in BDNF levels [38]. The pathophys-
iological role of BDNF BD has been reviewed in detail elsewhere
[38,39]. Several effective treatments for BD, such as lithium, elec-
troconvulsive therapy and atypical antipsychotics are known to in-
crease BDNF levels [40–42]. Moreover, polymorphisms of the BDNF
gene were shown to confer vulnerability to develop BD [43–45]. A
special attention has been given to the Val66Met polymorphism, asit appears to be signiﬁcantly associated with greater risk for BD
[43].
Curcumin and BDNF
Several preclinical studies revealed that curcumin is able to: (i)
induce widespread increases in brain BDNF levels; (ii) enhance the
expression of this neurotrophin and (iii) modulate the second mes-
sengers in BDNF signaling pathway [46].
Induction of stress and activation of hypothalamus–pituitary–
adrenal (HPA) axis in animals promotes a reduction in BDNF levels.
Curcumin restored BDNF levels in the hippocampus and prefrontal
cortex of rats when compared to control animals submitted to cor-
ticosterone-induced animal models of depression [47]. In addition,
administration of curcumin completely reversed the alterations in
BDNF and its mRNA expression in the hippocampus of pigs submit-
ted to stress [47]. The BDNF signaling pathway in the hippocampus
has been implicated in the neurogenesis and neuroprotection
machinery that maintains homeostasis and ensure neuronal sur-
vival in humans [48]. The hippocampus is also suggested as a ma-
jor target for curcumin’s anti-stress activity in rodents and humans
[49].
Studies in primary neuronal cultures found that curcumin en-
hanced neuronal survival by 21% by day 6 when compared to con-
trol cells [50]. To investigate if the BDNF receptor activation was
involved in these neuroprotective effects, Wang and cols [50]
blocked the BDNF receptor TrkB with a speciﬁc antibody. The
application of an anti-TrkB IgG inhibited curcumin’s effects upon
neuronal survival in vitro [50]. Curcumin also stimulates the syn-
thesis of BDNF in a dose-dependent manner [50]. In addition, cur-
cumin increased the phosphorylation of TrkB, indicating that the
BDNF/TrkB signaling pathway was activated by this compound.
Two well-known downstream mediators of BDNF intracellular ef-
fects, MAPK–ERK and PI-3K/AKT were also investigated as putative
curcumin targets. Curcumin treatment led to the phosphorilation
(i.e., activation) of both mediators, thereby indicating that this
substance act on important points in the BDNF signaling cascade
[50]. Furthermore, curcumin upregulates cAMP response element-
binding (CREB) phosphorylation, a pathway known to regulate
BDNF transcription, in cortical neurons reaching a maximum effect
after 6 h [50]. Finally, pretreatment with curcumin reverses the
downregulation of BDNF and phosphorylated-TrkB induced by
glutamate in cultured cortical neurons [51].
Oxidative stress
An excessive production of reactive oxygen species (ROS) or
deﬁciency in antioxidant mechanisms leads to oxidative stress,
which, in turn, may promote apoptosis or necrosis [52], along with
brain damage [14]. Several lines of evidences relate oxidative stress
mechanisms to BD [53,54]. Previous studies demonstrate both
reduction and overactivity of defenses against oxidative damage
as well as increases in ROS [54]. Although the ﬁndings are hetero-
geneous, alterations in antioxidant enzymes, such as an increase in
superoxide dismutase (SOD) in both depressive and manic epi-
sodes were demonstrates (2). Catalase was found to be increased
in mania [55] and decreased in euthymia (2). Markers of lipid per-
oxidation, like thiobarbituric acid reactive substances (TBARS), as
well as nitric oxide (NO), have also been shown to be increased
in major mood episodes of BD, regardless of polarity [54]. Post mor-
tem brain investigations revealed that SOD and catalase expression
are consistently decreased in the hippocampus of BD patients [56].
Furthermore, a down-regulation of several mitochondrial-related
genes, such as the ATP synthase and cytochrome-c oxidase genes
in the hippocampus [57] and dorsolateral prefrontal cortex of BD
patients were reported [53]. These reductions in gene expression
could lead to mitochondrial dysfunction, shifting metabolism
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tion of ROS.
Anti-oxidant actions of curcumin
There is consistent evidence that, in the presence of an oxida-
tive challenge, curcumin can exhibit antioxidant properties and
act as a ROS scavenger [58–60]. In an animal model of alcohol-
induced neuropathy, curcumin treatment markedly decreases
elevated levels of endogenous nitric oxide [61]. In addition, curcu-
min treatment for 21 days before transport, which was used as a
stressor, effectively prevented stress-induced elevation in NO
production in the hippocampus of pigs [47]. Curcumin treatment
also attenuated the stress induced up-regulation in the enzyme
NOS along with an increase in mRNA expression of NOS to levels
that were not signiﬁcantly different from a healthy control group
[47].
Cellular effects of oxidative stress also can be antagonized by
curcumin, as it prevented DNA damage in a model of alcoholic neu-
ropathy [61].
There is interplay between pathways involved in oxidative
stress and those related to inﬂammation. Inhibition of NOS in acti-
vated macrophages can result in an anti-inﬂammatory effect [62].
Inﬂammation
The immune and the central nervous system are widely inter-
connected and inﬂuence each other on a bidirectional way. Inﬂam-
matory markers directly inﬂuence neurotransmitter function [63]
and neural plasticity pathways [64]. The role of inﬂammation in
the pathophysiology of mental disorders has been studied for dec-
ades and data supporting this association is convincing [65]. In BD,
increases in pro-inﬂammatory markers, such as C-reactive protein
(CRP), soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6)
and tumor necrosis factor-alpha (TNF-a), are observed in mania
and in depression [66]. Changes in some of these markers, such
as sIL-2R and IL-6, have also been associated with treatment or
symptomatic improvement [66]. In euthymia, a few studies found
differences between patients and controls [67,68]. Length of illness
was also associated with altered levels of pro-inﬂammatory mark-
ers, with a decrease in IL-6 and an increase in TNF-a in late com-
pared with early stages of BD [69].
Effects of curcumin in inﬂammation
Prostaglandins pathway. Cyclooxygenase is a prostaglandin H syn-
thase, which converts arachidonic acid released by membrane
phospholipids in prostaglandins. Two isoforms of prostaglandin
H synthase, COX-1 and COX-2 have been identiﬁed. COX-1 is con-
stitutively expressed in many tissues, but COX-2 is regulated by
several factors, including mitogens, cytokines and growth factors
[70]. There is a consistent body of evidence that curcumin is a po-
tent modulator of pro-inﬂammatory enzymes (cyclooxygenases
[COX] and lipooxygenases) and inﬂammatory transcription factors
involved in transduction of signal of inﬂammatory mediators, like
IL-1b and IL-6 [71]. Curcumin is not only able to inhibit COX-2
but also to down-regulate COX-2 gene expression [72].
Interestingly, there are evidences for the participation of alter-
ations of arachidonic acid cascade in the pathophysiology of BD
[73]. The acid arachidonic cascade is activated by several stimuli
such as inﬂammation and excitotoxicity [73]. In addition, conven-
tional mood stabilizers like lithium, valproic acid and carbamaze-
pine reduce the production of arachidonic acid [32,74]. In a post
mortem brain study, the mRNA levels of several components of
the arachidonic acid cascade were abnormal in BD patients, includ-
ing COX-2 levels [73], thereby reinforcing the hypothesis that this
pathway is disturbed in BD. Interestingly, the COX-2 antagonist,
celecoxib, demonstrated possible efﬁcacy over placebo in reducingdepressive symptoms in a randomized controlled trial of individu-
als with BD [75].Microglial activation. There is some preliminary evidence that cur-
cumin treatment effectively reduces microglial activation. This was
demonstrated in a study that examined 49 different transcripts in
microglial cells [76]. In this study, curcumin treatment triggered
anti-inﬂammatory signals as shown by induction of expression of
IL-4 and peroxisome proliferator activated receptor alpha [76].
Curcumin also blocked gene expression related to pro-inﬂamma-
tory activation of resting cells such as Toll-like receptor and pros-
taglandin-endoperoxide synthase-2 [76]. In addition, in a study
with a Alzheimer transgenic mouse model, curcumin at low doses
reduced microglial activation, as indicated by lower levels of glial
ﬁbrillary acidic protein (GFAP), along with a reduction inﬂamma-
tion mediated by microglia in mouse hippocampus and cortex
[77]. Taking together, these studies indicate that curcumin attenu-
ates microglial activation, thereby promoting anti-inﬂammatory
and neuroprotective effects.Cytokines. Curcumin reduces inﬂammatory cytokines, including
TNF-a and interleukin-1b in a model of alcoholic neuropathy
[61]. TNF-a is a cytokine secreted by monocytes and lymphocytes
that kills tumoral cells in vivo. Inﬂammatory diseases, including
BD, are characterized by increases in TNF-a [78] that exert its ef-
fects in target cells using second messengers such as NFjB. NFjB
is a transcription factor located in the cytoplasm. It is activated
by several stimuli, including ROS, IL-1, TNF-a. Normally NFjB
binds to an inhibitory protein, called IkB. Once activated, the bind-
ing between KFjB and IkB is broken and NFjB is transported to the
nucleus, where it promoted the transcription of several genes,
depending on cell type. In glial cells, it activates the transcription
of TNF-a [78]. Curcumin has also been reported to suppress the
activity of NFjB in vitro and in vivo, and this suppression has been
considered a critical mechanism for protection against incident
cancer [79].
Activity of NFjB also has been considered as a relevant modula-
tor of chemokine levels. These cytokines with chemoatractive
properties exert a critical role in ampliﬁcation and regionalization
of the inﬂammatory response, because they are able to recruit neu-
trophils, monocytes and macrophages to the site of inﬂammation.
Some lines of evidence indicate that curcumin inhibits the secre-
tion of chemokines, such as CCL24, through suppression of the
NFjB pathway [80]. Increments in serum levels of pro-inﬂammatory
chemokines has been found in euthymic BD patients [80].Apoptosis
Apoptosis or programmed cell death is essential to the mainte-
nance of cellular homeostasis in multicellular organism [81]. It has
a crucial role during brain development stages [81]. There is a
growing body of evidence that neuropsychiatric disorders are re-
lated to deregulation of apoptotic mechanisms, with increased cell
death [81,82].
In BD studies have shown increased pro-apoptotic serum activ-
ity [83]. Additionally imaging studies show decreased cortical
thickness, which might be related to neuronal loss [84]. A post mor-
tem study showed signiﬁcant increases in protein and mRNA levels
of the pro-apoptotic factors (Bax, BAD, active Caspase-3 and -9)
and signiﬁcant decreases of levels of the anti-apoptotic factors
(Bcl-2, BDNF) [85]. Moreover treatment with Lithium or Valproate
affects apoptosis by suppression of caspase-3 activity and
stimulates B-cell lymphoma-2 (Bcl-2) expression, which has anti-
apoptotic action [86–88].
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Curcumin has a role in regulating apoptotic mechanisms. A
study showed that curcumin regulated 104 genes out of 214 genes
associated with apoptosis in tumor cells [89]. It has also been
demonstrated that curcumin inhibits apoptosis in a mice model
of Parkinson disease [90] and in iron induced necroptosis [91].
The precise role of curcumin in apoptotic mechanism still remains
to be fully elucidated, but, because it seems to exert an anti-
apoptotic effect, it is a candidate as a possible beneﬁcial medication
in BD [92].Behavioral effects of curcumin in preclinical studies
Curcumin has been tested in several animal models of depres-
sion showing antidepressant-like properties [93]. This antidepres-
sant proﬁle has been veriﬁed in classical predictive models, such as
the tail suspension test (TST) and the forced swimming test (FST)
[94–100]. Additionally, the effect of curcumin treatment was com-
parable in magnitude to the effects observed for classical antide-
pressants, such as ﬂuoxetine and imipramine [97]. Furthermore,
curcumin also potentiated sub-therapeutic doses of ﬂuoxetine,
venlafaxine and bupropion in the FSR or TST [95]. These behavioral
effects of curcumin were accompanied by an increase in brain sero-
tonin and dopamine levels and inhibition of MAO activities
[94,95,100]. Conversely, the beneﬁcial effect of curcumin was sup-
pressed by a prior serotonin depletion induced by the tryptophan
hydroxylase inhibitor p-chlorophenylalanine [98].
Curcumin also exhibited positive results in models where
depression was induced by environmental or pharmacological
manipulations. In the chronic unpredictable stress paradigm in
rats, repeated curcumin treatment was able to reverse the in-
creases in immobility and in MAO activity as well as the depletion
of brain monoamines [101]. In the same way, curcumin amelio-
rated the low sucrose consumption (an anedonia-like behavior)
and the increase in serum corticosterone levels induced by this
same paradigm [102]. Furthermore, curcumin promoted decreases
in BDNF levels and in the pCREB/CREB ratio [46]. Finally, effective
doses of curcumin for behavioral alterations induced by the
chronic unpredictable stress paradigm also increased hippocampal
neurogenesis similarly to classical antidepressants [49].
Administration of curcumin also reversed the corticosterone-
induced depressive behavior in rats, as well as the decrease in
sucrose consumption and the immobility time [103]. Additionally,
these behavioral effects were accompanied by the reversal of the
corticosterone-induced decrease in BDNF levels in hippocampus
and frontal cortex [103].
A beneﬁcial effect of curcumin was also described in a pain-
depression dyad model [104]. In this model, rats treated with
reserpine show a decrease in nociceptive threshold and an increase
in immobility time accompanied by a decrease in dopamine,
serotonin and norepinephrine along with increased substance P
concentration and inﬂammatory cytokines in cortex and hippo-
campus. Curcumin ameliorated these behavioral and biochemical
alterations induced by reserpine [104].
Finally, curcumin administration was able to reverse the behav-
ioral changes induced by the olfactory bulbectomy animal model
of depression – which consists of bilateral removal of the olfactory
bulbs inducing neurochemical, neuroendocrine and immune
changes mimicking alterations seen in depression. Further, curcu-
min also reversed the decrease in norepinephrine, serotonin, and
dopamine levels in the frontal cortex of rats submitted to this pro-
cedure [100].
The effects of curcumin in CNS are not limited to depression
models. One study in rats demonstrated that curcumin was able
to prevent haloperidol-induced abnormal oro-facial movements[25]. These antidyskinetic effects were shown to be mediated by
an induction of gene transcription of Bcl-XL, an antioxidant impli-
cated in the prevention of cell death, in the striatum [25].Curcumin in clinical trials
Curcumin has been investigated in several preliminary clinical
trials for a myriad of inﬂammatory conditions, neuropsychiatric
disorders and cancer [105]. Regarding non-psychiatric conditions,
curcumin was tested in the treatment of rheumatoid arthritis in
a double-blind crossover study. There was signiﬁcant improve-
ment in morning stiffness, walking time and joint swelling [106].
A non-controlled study with curcumin in gel in treatment of psori-
asis showed either resolution or reduction in plaques following
8 weeks of treatment [107]. Two studies have found curcumin to
have a positive effect in inﬂammatory bowel disease, with one ran-
domized controlled trial showing those 6 months of daily doses of
curcumin improved symptoms and maintained remission
[108,109]. In individuals submitted to kidney transplantation,
one study of 43 patients found a positive effect of curcumin on
the reduction of acute rejection rates and neurotoxicity over a
course of 6 months [110].
The ﬁrst evidence for a potential role of curcumin in the preven-
tion and treatment of neuropsychiatric conditions came from
uncontrolled studies. A large prospective study comparing a rural
sample from India and a reference population in the US found low-
er incidence of Alzheimer’s disease in the Indian population [111].
Among the factors associated with the low incidence of AD, dietary
factors and the consumption of natural products were implicated
[111]. Curcumin also has been shown to improve spatial memory
impairment induced by a human immunodeﬁciency virus (HIV)
cognitive deﬁcit model [112].
Regarding clinical trials, Ringman and collaborators [113] con-
ducted a clinical trial to evaluate tolerability and safety of curcu-
min at dose of 2000 mg/day and 4000 mg/day in patients with
mild to moderate AD and healthy controls. In 6 months, random-
ized, placebo-controlled for individuals with dementia, curcumin,
in addition to its clinical effect, increased plasma levels of vitamin
E when compared to placebo [114].Considerations about pharmacokinetics of curcumin
Animal and human studies of curcumin pharmacokinetics re-
vealed that a relatively poor absorption and rapid metabolism of
curcumin reduces its bioavailability [115]. Curcumin is rapidly
metabolized in animals, conjugated in the liver, and excreted in
the feces with minimal amounts found in the urine [115]. More-
over it is sparingly soluble in water, which is one of the reasons
for its poor absorption through oral route, being the reason for
the use of high doses of this compound in clinical trials (typically
more of 1000 mg/day) [22]. In a study by Pan et al. [116], in mice,
a curcumin dose of 0.1 g/kg via i.p. route showed a minimum
amount in the brain tissue after 1 h (0.4 lg/g). Brain curcumin level
peaked at 2.9 (±0.4) nmol/g of tissue, in an analysis following
administration of [14C] curcumin (100 mg/kg) via the i.p. route
and monitoring for the disappearance of radioactivity associated
with the molecule. Radioactive levels declined rapidly in all tissues
[117,118]. A phase I clinical trial conducted on 25 patients with
precancerous lesions showed oral doses of 4, 6, and 8 g curcumin
daily for three months yielded serum curcumin concentrations of
only 0.51 ± 0.11, 0.63 ± 0.06, and 1.77 ± 1.87 lM respectively, indi-
cating poor absorption of straight curcumin. In addition, curcumin
levels peaks in plasma one or two hours following per os adminis-
tration and declines rapidly, within 12 h [119].
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curcumin with caution, since this compound may cause gallblad-
der contractions. In a randomized, double-blind, crossover study
involving 12 healthy volunteers, 20 mg curcumin produced as
much as 29% reduction in gallbladder size, indicating gallbladder
contraction [120]. A subsequent study conﬁrmed this ﬁnding
[121]. Curcumin also inhibits platelet aggregation in vitro and in
animal studies [122,123].
Poor absorption and rapid metabolism are a limiting factor for
the clinical use of curcumin. To surpass the relatively low bioavail-
ability of this compound, patients need to take high doses of this
drug. Although non-toxic, these high doses (as high as 12 g/day)
may decrease the tolerability of some patients [21,118]. Neverthe-
less, curcumin at high doses has shown to be helpful in pancreatic
cancer, which indicates that its therapeutic potential could be
limited by dosing considerations [21]. These pharmacokinetic
obstacles led to the development of curcumin analogs with higher
potency, slower metabolism and increased absorption [21].
Examples of curcumin analogs include: 3,5-bis(2-ﬂuorobenzylid-
ene)-4piperidone (EF24) and 3,5-bis(2-pyridinylmethylidene)-
4piperidone (EF31). Another possible strategy to overcome these
pharmacokinetic barriers e is the development of a phytosome,
complexing curcumin with phosphatidylcholine [71]. The resulting
compound has been patented with the name of Meriva [71].Future perspectives
As discussed in previous sections, most beneﬁcial effects of cur-
cumin are supported by preclinical, epidemiological and studies.
Interestingly, there are no clinical studies of curcumin in mental
disorders to date and the evidences in other medical conditions
are still incipient [71]. Curcumin is not the ﬁrst CAM to be postu-
lated as potentially useful in BD. Substances like L-tryptophan,
Omega-3 fatty acids, St. John’s Worth, S-adenosyl-I-metyonine
(SAMe) and treatments like massage therapy and acupuncture
have been proposed [19,124]. Many of these treatments turned
out to be ineffective at best and harmful at worst [124].
The history of overstatement of beneﬁt and under delivery of
results in the past resulted in scientiﬁc skepticism about CAM
interventions for the treatment of mental disorders, including
BD. The current conceptual models of the patho-etiology of BD
align with several of the biological targets proposed for curcumin,
suggesting that it may have a salutary role in this condition. The
unmet needs in BD are notably for agents targeting depressive
symptoms/episodes and cognitive impairment. Future clinical tri-
als of curcumin could include either or both of these psychopath-
ological domains as the principle targets of interest.
The development of new curcuminoid formulations would
overcome some pharmacokinetic barriers to the clinical use of cur-
cumin. These novel congeners would hopefully have a greater bio-
availability and a better prediction of clinical response when
compared to the original compound.Conﬂict of interest
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